M

Maat Pharma SA
PAR:MAAT

Watchlist Manager
Maat Pharma SA
PAR:MAAT
Watchlist
Price: 7.88 EUR -1.5% Market Closed
Market Cap: 109.5m EUR
Have any thoughts about
Maat Pharma SA?
Write Note

Wall Street
Price Targets

MAAT Price Targets Summary
Maat Pharma SA

Wall Street analysts forecast MAAT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MAAT is 16.49 EUR with a low forecast of 13.94 EUR and a high forecast of 22.05 EUR.

Lowest
Price Target
13.94 EUR
77% Upside
Average
Price Target
16.49 EUR
109% Upside
Highest
Price Target
22.05 EUR
180% Upside
Maat Pharma SA Competitors:
Price Targets
MREO
Mereo Biopharma Group PLC
112% Upside
300896
Imeik Technology Development Co Ltd
39% Upside
ALVO
Alvotech SA
73% Upside
377740
BioNote Inc
20% Upside
LGND
Ligand Pharmaceuticals Inc
11% Upside
INCY
Incyte Corp
17% Upside
ITOS
Iteos Therapeutics Inc
244% Upside
DNLI
Denali Therapeutics Inc
103% Upside

Revenue
Forecast

Revenue Estimate
Maat Pharma SA

The compound annual growth rate of Maat Pharma SA's revenue for the next 4 years is 129%.

N/A
Past Growth
129%
Estimated Growth
Estimates Accuracy
-26%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Maat Pharma SA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-7%
Average Miss

Net Income
Forecast

Net Income Estimate
Maat Pharma SA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-26%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is MAAT's stock price target?
Price Target
16.49 EUR

According to Wall Street analysts, the average 1-year price target for MAAT is 16.49 EUR with a low forecast of 13.94 EUR and a high forecast of 22.05 EUR.

What is Maat Pharma SA's Revenue forecast?
Projected CAGR
129%

The compound annual growth rate of Maat Pharma SA's revenue for the next 4 years is 129%.

Back to Top